Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 15/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurokinin B SCHEMBL29390479 | 1.00 | GRPR (0.59) | GRPR | |
| SCHEMBL30350156 | 0.94 | TACR3 (0.57) | GRPR | |
| SCHEMBL29406603 | 0.90 | CTSB (0.54) | — | |
| Neurokinin A SCHEMBL29374005 | 0.88 | PTH1R (0.62) | — | |
| Neurokinin A SCHEMBL29374084 | 0.88 | PTH1R (0.62) | — | |
| Neurokinin B SCHEMBL29372314 | 0.88 | GRPR (0.53) | GRPR | |
| SCHEMBL29569383 | 0.87 | OPRM1 (0.57) | GRPR | |
| SCHEMBL29678561 | 0.86 | CCKAR (0.51) | — | |
| SCHEMBL29678344 | 0.84 | NPY4R (0.56) | — | |
| SCHEMBL14364816 | 0.84 | GRPR (0.58) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695385-A1 | GENE EDITING FOR INTERVERTEBRAL, INTRA- AND PERIDISCAL THERAPY AND ASSOCIATED SPINAL DISORDERS | Orthobio Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694913-A2 | LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS | Orthobio Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | UMOJA BIOPHARMA, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4180799-B1 | METHOD OF CLASSIFYING MILK | PPB TECH PTY LTD (AU) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382586-A1 | MANUFACTURING VIRAL PARTICLES | UMOJA BIOPHARMA, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | Umoja Bioharma, Inc. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | disclosed |
| US-20250354118-A1 | COMPOSITIONS AND METHODS FOR NK CELL DIFFERENTIATION | UMOJA BIOPHARMA, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025235604-A1 | FUSION PROTEIN FOR USE AS IMMUNE CELL ENGAGER | UMOJA BIOPHARMA, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20230145413-A1 | FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-11610650-B2 | Method and system for designing polynucleotide sequences and polynucleotide sequences obtained thereby | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-03-21 | — | — | US | disclosed |
| US-20220314221-A1 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-10-06 | — | — | US | disclosed |
| US-11434275-B2 | Fast-off rate serum albumin binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-06 | — | — | US | disclosed |
| US-11396012-B2 | Microfluidic device for analyzing gene expression | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-07-26 | — | — | US | disclosed |
| US-11385234-B2 | Methods and systems for detecting an analyte or classifying a sample | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2022-07-12 | — | — | US | disclosed |
| US-20220204589-A1 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS | BRISTOL-MYERS SQUIBB COMPANY | 2022-06-30 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3572424-B1 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | IL2RA, IL2, IL15RA | GRPR 385/4885 |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GRPR 936/4885 |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | GRPR 4759/4885 |
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | BMP4, FLT4, FGF2 | GRPR 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.